The table below shows Revolution Medicines, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$354.17M
-$194.44M
-$160.56M
-$62.39M
-$55.16M
-$37.25M
Capital expenditure
$1.54M
$3.27M
$3.17M
$1.76M
$1.89M
$3.58M
Investing cash flow
$172.62M
-$15.95M
-$247.97M
$4.00M
$44.02M
$2.31M
Dividends paid
-
-
-
-
RVMD operating cash flow (10-K history)
Revolution Medicines, Inc. reported operating cash flow of -$897.74M for fiscal year 2025. That is down 61.0% from -$557.44M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from $1.21M (FY 2018) to -$897.74M. Figures come from the company's audited annual reports as filed with the SEC.